Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axogen (AXGN) Gains from Sales and Divestitures (2017 - 2020)

Axogen's quarterly Gains from Sales and Divestitures came in at $168311.0 in Q3 2020, up 94.79% quarter-over-quarter from $86405.0 in Q4 2019.

Axogen has reported Gains from Sales and Divestitures for 4 years, with the latest figure at $168311.0 in Q3 2020.

  • For the quarter ending Q3 2020, Gains from Sales and Divestitures changed N/A year-over-year to $168311.0; the trailing twelve-month figure through Sep 2020 stood at $168311.0 (changed N/A YoY), and the FY2019 full-year result was $86405.0, up 1108.46% from the prior year.
  • Gains from Sales and Divestitures for Q3 2020 stood at $168311.0, up from $86405.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $168311.0 in Q3 2020, with the low at $7150.0 in Q4 2017.
  • Average Gains from Sales and Divestitures over 4 years is $67254.0, with a median of $46777.5 recorded in 2017.
  • Year-over-year, Gains from Sales and Divestitures changed 0.0% in 2018 and jumped 1108.46% in 2019.
  • Tracing AXGN's Gains from Sales and Divestitures over 4 years: stood at $7150.0 in 2017, then changed by 0.0% to $7150.0 in 2018, then jumped by 1108.46% to $86405.0 in 2019, then jumped by 94.79% to $168311.0 in 2020.
  • The last three Gains from Sales and Divestitures figures came in at $168311.0 (Q3 2020), $86405.0 (Q4 2019), and $7150.0 (Q4 2018), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Axogen 2.00 Bn 1.90 Bn 46.19 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2020 168,311.00
Sep 30, 2020 168,311.00
Dec 31, 2019 86,405.00
Dec 31, 2019 86,405.00
Dec 31, 2018 7,150.00
Dec 31, 2018 7,150.00
Dec 31, 2017 7,150.00
Dec 31, 2017 7,150.00